On October 28, 2020 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported that its Chairman, Chief Executive Officer and President and Founder, Powering Precision Health (PPH), Kevin Hrusovsky, will speak today at the Precision Medicine Leaders Summit’s (PMLS) Precision Oncology Conference (Press release, Quanterix, OCT 28, 2020, View Source [SID1234569252]). Hrusovsky’s keynote presentation, "Revolutionizing Cancer Treatment and Detection with Biomarkers," will take place at 3:15 p.m., EDT. To register for today’s event visit, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During his presentation, Hrusovsky will discuss advances in highly sensitive multiplex assays, which are enabling researchers to identify and quantify multiple oncology biomarkers simultaneously. This insight paired with the unprecedented ability to see biomarkers in minute concentrations in the blood, as enabled by ultra-sensitive biomarker platforms, is creating new pathways for detecting cancer at its earliest stages. Hrusovsky’s keynote will also speak to the important role of biomarkers in improving the efficacy and safety of immuno-oncology-based treatments by empowering researchers to optimize dosing and minimize toxicity associated with severe side effects.